MedTrace Logo

Interest of Eosinopenia to Predict In-hospital Mortality Among Elderly Patients

NCT04734431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 224

Last updated 2021-02-02

No results posted yet for this study

Summary

No biological marker is highly specific of infection and currently available, especially for bacterial infection. The ideal marker would be easy to perform, rapidly, inexpensive, and correlated with the severity and prognosis of the infection.

decreased in eosinophil count (EC) is unspecific of a particular clinical picture and may support a systemic inflammation, whereas the deeper the eosinopenia is, the darker is the prognosis in ICU.

The duration of eosinopenia is not clearly documented, but it has been recently shown that EC tends to normalization, rapidly after appropriate and effective antimicrobial therapy in case of bacterial infection among adults patients hospitalized in a medicine ward. In the light of this findings, Terradas et al. described that EC returned back to normal between the day 2 or day 3 in survivors, indicating a potential interest as a predictive marker of the evolution among hospitalized patients.

To the best of our knowledge, no work has studied eosinopenia as a prognostic marker of mortality during bacterial infections in the elderly patients in a hospital setting. Our study aims to evaluate the prognosis value of the EC in a geriatric unit of tertiary care hospital.

Conditions

Interventions

BIOLOGICAL

Eosinophil count

Evaluation of the eosinophil count from admission to day 7

Sponsors & Collaborators

  • Centre d'Investigation Clinique et Technologique 805

    lead OTHER

Principal Investigators

  • BENJAMIN DAVIDO, MD · Hopital Raymond Poincaré

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-12-31
Completion
2020-01-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734431 on ClinicalTrials.gov